Injectable PrEP Access Uncertain During ACA Open Enrollment
- Okay, here's a breakdown of the key takeaways from the provided text, focusing on coverage of Lenacapavir (a PrEP drug) and the challenges in determining that coverage:
- * High Coverage Rate: Gilead reports 75% coverage of Lenacapavir, including both private and public payers.
- Lenacapavir is administered by a healthcare provider, meaning it can be billed as a "medical benefit" rather of a "pharmacy benefit." * Impact: If billed as a...
Okay, here’s a breakdown of the key takeaways from the provided text, focusing on coverage of Lenacapavir (a PrEP drug) and the challenges in determining that coverage:
Key Findings Regarding Lenacapavir Coverage:
* High Coverage Rate: Gilead reports 75% coverage of Lenacapavir, including both private and public payers.
* favorable Coverage Terms: Most payers are covering the drug without prior authorization or cost-sharing. Some marketplace plans (Oscar in NY & IL, Molina in IL) even list it as a preventive medication with zero cost-sharing.
* USPSTF Uncertainty: The status of an updated USPSTF (U.S. Preventive services Task Force) suggestion for PrEP is unclear. (This is important as USPSTF recommendations often lead to mandated coverage).
Challenges in Determining Coverage:
* Medical vs. pharmacy Benefit: This is the biggest issue. Lenacapavir is administered by a healthcare provider, meaning it can be billed as a “medical benefit” rather of a ”pharmacy benefit.”
* Impact: If billed as a medical benefit,it may not appear on standard drug formularies or in drug search tools.This makes it difficult for consumers to verify coverage.
* UnitedHealthcare Example: In New York and Texas (using Optum as a PBM), the formulary specifically states Lenacapavir isn’t covered under the pharmacy benefit and directs users to check their medical policy. However, Gilead states the issuer is covering the drug.
* Lack of Cost-Sharing Clarity (Medical Benefit): Even if a plan covers it as a medical benefit, it’s not always clear what (if any) cost-sharing applies.
* Marketplace Search Tool Inaccuracies:
* Varying functionality: Marketplace tools differ in whether they allow drug coverage checks. Some don’t offer the feature at all (e.g., New York’s marketplace).
* Inaccurate Results: Even when search tools are available, they can be inaccurate.
* Oscar (Texas): The federal marketplace shows Oscar plans don’t cover Lenacapavir, but Oscar’s formulary does list it as covered preventive.
* Illinois: The Illinois marketplace tool doesn’t even recognize the drug, despite some formularies showing coverage.
* Medical Benefit “Hidden” from Tools: The text suggests that if Lenacapavir is covered as a medical benefit, marketplace search tools (which rely on formulary data) likely won’t display accurate coverage data.
In essence, the text highlights a situation where coverage for a crucial preventative medication exists, but is difficult for consumers to confirm due to complexities in how health plans administer and report coverage.
Let me know if you’d like me to elaborate on any specific point or analyze the implications of these findings.